Skip to main content

Progress new assets (one pre-new molecular entity and one first-time-in-human start) for tuberculosis that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitors

Objective

Despite recent progress in biomedical research, Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis (TB), is still the world’s leading infectious disease killer worldwide. In addition, multi-drug TB is the largest single contributor to anti-microbial resistance and poses a serious threat to global health. Treatment options are limited, and expensive, recommended medicines are not always available in many countries, and patients experience many adverse effects from the drugs. Moreover, due to the long treatment duration, compliance is low leading to more AMR in TB. Thus, there is an acute need for the development of a novel combination regimen with an indication for effective, shorter, and safer treatment of all forms of TB. The overall objective of RESPIRI-TB is to find new drug candidates as potential components of a new, more efficient combination drug regimen against TB that is less prone to resistance and allows shortening of treatment duration for TB, and multidrug-resistant TB. Such a drug combination will synergistically target the energy metabolism of Mtb or complementary targets. To achieve this, we will advance recently discovered inhibitors of the Mtb respiratory pathway. In addition, we will target the Mtb specific molecular mechanism that reduces reactive oxygen species in the cell. Finally, we will also target host-factors that are essential for the intracellular survival of Mtb. Together, we present a comprehensive plan to find novel strategies to combat TB, shorten treatment time and reduce chances of drug resistance.

Field of science

  • /medical and health sciences/basic medicine/pharmacology and pharmacy/drug resistance
  • /medical and health sciences/clinical medicine/pneumology/tuberculosis

Call for proposal

H2020-JTI-IMI2-2018-16-single-stage
See other projects for this call

Funding Scheme

IMI2-RIA - Research and Innovation action

Coordinator

ACADEMISCH ZIEKENHUIS LEIDEN
Address
Albinusdreef 2
2333 ZA Leiden
Netherlands
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 968 282,50

Participants (8)

UNIVERSITEIT LEIDEN
Netherlands
EU contribution
€ 124 375
Address
Rapenburg 70
2311 EZ Leiden
Activity type
Higher or Secondary Education Establishments
UNIVERSITEIT ANTWERPEN
Belgium
EU contribution
€ 4 179 723,34
Address
Prinsstraat 13
2000 Antwerpen
Activity type
Higher or Secondary Education Establishments
SORBONNE UNIVERSITE
France
EU contribution
€ 343 875
Address
21 Rue De L'ecole De Medecine
75006 Paris
Activity type
Higher or Secondary Education Establishments
MEDIZINISCHE UNIVERSITAET WIEN
Austria
EU contribution
€ 813 125
Address
Spitalgasse 23
1090 Wien
Activity type
Higher or Secondary Education Establishments
KOBENHAVNS UNIVERSITET
Denmark
EU contribution
€ 99 638,53
Address
Norregade 10
1165 Kobenhavn
Activity type
Higher or Secondary Education Establishments
JANSSEN PHARMACEUTICA NV
Belgium
EU contribution
€ 0
Address
Turnhoutseweg 30
2340 Beerse
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
MITOLOGICS
France
EU contribution
€ 146 630,63
Address
Avenue Gaston Roussel 102
93230 Romainville
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
FFUND BV
Netherlands
EU contribution
€ 164 350
Address
Barbara Strozzilaan 101
1083 HN Amsterdam
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)